Concise Article
MedChemComm
References
15 J. Hou, et al., Structure-based optimization of click-based
histone deacetylase inhibitors, Eur. J. Med. Chem., 2011, 46,
3190–3200.
16 L. Chen, et al., Dual inhibitors of inosine monophosphate
dehydrogenase and histone deacetylase based on a cinnamic
hydroxamic acid core structure, Bioorg. Med. Chem.,
2010, 18, 5950–5964.
1
O. Khan and N. B. La Thangue, HDAC inhibitors in cancer
biology: emerging mechanisms and clinical applications,
Immunol. Cell Biol., 2012, 90, 85–94.
2
A. L. Clayton, et al., Enhanced histone acetylation and
transcription: a dynamic perspective, Mol. Cell, 2006, 23,
2
89–296.
17 S. Dallavalle, et al., Design, synthesis, and evaluation of
biphenyl-4-yl-acrylohydroxamic acid derivatives as histone
deacetylase (HDAC) inhibitors, Eur. J. Med. Chem., 2009, 44,
1900–1912.
18 E. H. Rubin, et al., A study to determine the effects of food
and multiple dosing on the pharmacokinetics of vorinostat
given orally to patients with advanced cancer, Clin. Cancer
Res., 2006, 12, 7039–7045.
19 G. Garcia-Manero, et al., Phase 1 study of the oral isotype
specific histone deacetylase inhibitor MGCD0103 in
leukemia, Blood, 2008, 112, 981–989.
20 P. A. Marks, Discovery and development of SAHA as an
anticancer agent, Oncogene, 2007, 26, 1351–1356.
21 K. Ververis, et al., Histone deacetylase inhibitors (HDACIs):
multitargeted anticancer agents, Biol.: Targets Ther., 2007, 7,
47–60.
22 A. A. Lane and B. A. Chabner, Histone deacetylase inhibitors
in cancer therapy, J. Clin. Oncol., 2009, 27, 5459–5468.
23 J. C. Wong, et al., Structural biasing elements for in-cell his-
tone deacetylase paralog selectivity, J. Am. Chem. Soc.,
2003, 125, 5586–5587.
24 P. G. Wang, et al., Discovery and extensive in vitro
evaluations of NK-HDAC-1: a chiral histone deacetylase
inhibitor as a promising lead, J. Med. Chem., 2012, 55,
3066–3075.
3
4
A. V. Bieliauskas and M. K. Pflum, Isoform-selective histone
deacetylase inhibitors, Chem. Soc. Rev., 2008, 37, 1402–1413.
R. Benedetti, et al., Targeting Histone Deacetylases in
Diseases: Where Are We?, Antioxid. Redox Signaling,
2
015, 23, 99–126.
5
P. A. Marks and R. Breslow, Dimethyl sulfoxide to vorinostat:
development of this histone deacetylase inhibitor as an
anticancer drug, Nat. Biotechnol., 2007, 25, 84–90.
C. Campas-Moya, Romidepsin for the treatment of
cutaneous T-cell lymphoma, Drugs Today, 2009, 45, 787–795.
D. C. Rees, M. Congreve, C. W. Murray and R. Carr,
Fragment-based lead discovery, Nat. Rev. Drug Discovery,
6
7
2
004, 3, 600–672.
8
9
P. J. Hajduk and J. Greer, A decade of fragment-based drug
design: strategic advances and lessons learned, Nat. Rev.
Drug Discovery, 2007, 6, 211–219.
J. Hou, et al., Discovery and extensive in vitro evaluations of
NK-HDAC-1: a chiral histone deacetylase inhibitor as a
promising lead, J. Med. Chem., 2012, 55, 3066–3075.
1
1
1
0 T. T. Tung, et al., New benzothiazole/thiazole-containing
hydroxamic acids as potent histone deacetylase inhibitors
and antitumor agents, Med. Chem., 2013, 9, 1051–1057.
1 D. J. Witter, et al., Benzo[b]thiophene-based histone
deacetylase inhibitors, Bioorg. Med. Chem. Lett., 2007, 17,
4
562–4567.
25 C. M. Marson, et al., Discovery of potent, isoform-selective
inhibitors of histone deacetylase containing chiral heterocy-
clic capping groups and a N-IJ2-aminophenyl)benzamide
binding unit, J. Med. Chem., 2013, 56, 6156–6174.
26 V. Patil, et al., 3-Hydroxypyridin-2-thione as novel zinc
binding group for selective histone deacetylase inhibition, J.
Med. Chem., 2013, 56, 3492–3506.
27 G. Wu, et al., Detailed analysis of grid-based molecular
docking: A case study of CDOCKER-A CHARMm-based MD
docking algorithm, J. Comput. Chem., 2003, 24, 1549–1562.
2 L. A. Hooven, et al., Effects of suberoylanilide hydroxamic
acid and trichostatin A on induction of cytochrome P450
enzymes and benzo[a]pyrene DNA adduct formation in
human cells, Bioorg. Med. Chem. Lett., 2005, 15, 1283–1287.
3 C. T. Chan, et al., Syntheses and discovery of a novel class of
cinnamic hydroxamates as histone deacetylase inhibitors by
multimodality molecular imaging in living subjects, Cancer
Res., 2014, 74, 7475–7486.
1
1
4 C. Ning, et al., Design, synthesis and biological evaluation of
di-substituted cinnamic hydroxamic acids bearing urea/thio-
urea unit as potent histone deacetylase inhibitors, Bioorg.
Med. Chem. Lett., 2013, 23, 6432–6435.
28 U. Pieper, et al., ModBase,
a database of annotated
comparative protein structure models, and associated
resources, Nucleic Acids Res., 2011, 39, D465–D474.
Med. Chem. Commun.
This journal is © The Royal Society of Chemistry 2015